Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 16;41:64. doi: 10.1186/s13046-022-02249-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — PAPTP-induced pathological CLL cell death in Eμ-TCL1 mice. a Scheme representing the adopted protocol for PAPTP treatment: mice were injected once a day for 5 consecutive days; after 2 days of recovery, mice were subjected again to 5 injections, once a day for 5 consecutive days. b-d The percentage of B (CD19⁺CD5⁺) CLL cells was assessed by flow cytometry on ex vivo peripheral blood cells from Eμ-TCL1 mice before and after intraperitoneal administration of DMSO or 5 nmol/g PAPTP. Data were obtained from 15 independent experiments for each condition. Statistical significance of differences was assessed with the Mann–Whitney test. Average differences between the post- and pre-treatment percentages of CD19⁺CD5⁺ cells are reported for each substance (b), as well as individual percentages before and after treatment (c-d). Statistical significance of differences was assessed with the Mann–Whitney test. e-g Percentages of CD19⁺CD5⁺ cells were assessed by flow cytometry on ex vivo cells from the peritoneal cavity (e), spleen (f), and bone marrow (g) of Eμ-TCL1 mice after i.p. administration of DMSO (or PAPTP)